AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1284152 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (0.4 mg)
Number of subjects: 24
Study 1284152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6331302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 39
Study 6331302 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 39
Study 31107046 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for PTSD
Number of subjects: 80
Study 31107046 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 29265934 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin treatment
Number of subjects: 63
Study 26654280 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16
Study 26654280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24572769 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and irrigated radiofrequency pulmonary vein isolation (CABG+PVI, n = 31)
Number of subjects: 95
Study 24572769 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and an irrigated radiofrequency modified mini‐maze procedure (CABG+MM, n = 30)
Number of subjects: 95
Study 24572769 — intervention group
Group type: COMPARATOR
Intervention: Isolated CABG (CABG alone, n = 34)
Number of subjects: 95
Study 21856721 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training of patellar tendon and static stretching exercises of quadriceps and hamstrings (Group A)
Number of subjects: 43
Study 21856721 — intervention group
Group type: COMPARATOR
Intervention: Eccentric training of patellar tendon (Group B)
Number of subjects: 43
Study 20604700 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep Active Minnesota (KAM) intervention
Number of subjects: 1049
Study 20604700 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1049
Study 18300224 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRO MAP
Number of subjects: 15
Study 18300224 — intervention group
Group type: COMPARATOR
Intervention: Standard MAP
Number of subjects: 15
Study 15942151 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen cream
Number of subjects: 45
Study 15942151 — intervention group
Group type: COMPARATOR
Intervention: Chlindamycine phosphate cream (placebo)
Number of subjects: 45
Study 12598351 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DOX) 60 mg/m2 alone
Number of subjects: 177
Study 12598351 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 60 mg/m2 and Cisplatin (CDDP) 50 mg/m2 every 4 weeks
Number of subjects: 177
Study 9890307 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 13
Study 9890307 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 to 0.2 mg/h nitroglycerin patch
Number of subjects: 13
Study 8635139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without tumor necrosis
Number of subjects: 299
Study 8635139 — intervention group
Group type: COMPARATOR
Intervention: Patients with tumor necrosis
Number of subjects: 299
Study 2017970 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status score < 8
Number of subjects: 849
Study 2981827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg injections)
Number of subjects: 20
Study 2981827 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (50 mg injections)
Number of subjects: 20
Study 29902939 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily early therapeutic mobility (ETM)
Number of subjects: 54
Study 29902939 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity (out-of-bed) ETM
Number of subjects: 54
Study 29902939 — intervention group
Group type: COMPARATOR
Intervention: Once-daily early therapeutic mobility (ETM)
Number of subjects: 54
Study 29902939 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (in-bed) ETM
Number of subjects: 54
Study 27814865 — intervention group
Group type: COMPARATOR
Intervention: Hip muscle strengthening exercises (E)
Number of subjects: 18
Study 27814865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening exercises with myofascial techniques (EM)
Number of subjects: 18
Study 25475143 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 10
Study 25475143 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement (OFD)
Number of subjects: 10
Study 25475143 — intervention group
Group type: COMPARATOR
Intervention: Control (OFD)
Number of subjects: 10
Study 23759286 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral therapy including a virtual reality protocol (ECT)
Number of subjects: 90
Study 23759286 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavior therapy (CBT)
Number of subjects: 90
Study 23759286 — intervention group
Group type: COMPARATOR
Intervention: Inpatient multimodal treatment (IP)
Number of subjects: 90
Study 21235604 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 51
Study 21235604 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 51
Study 21235604 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (IFX)
Number of subjects: 51
Study 18504392 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 40
Study 18504392 — intervention group
Group type: COMPARATOR
Intervention: GH untreated
Number of subjects: 40
Study 17179478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (reduced fat intake)
Number of subjects: 2437
Study 17179478 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 2437
Study 15573624 — intervention group
Group type: EXPERIMENTAL
Intervention: Donut round
Number of subjects: 106
Study 15573624 — intervention group
Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 106
Study 11066464 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Program (antenatal smoking cessation intervention)
Number of subjects: 0
Study 11066464 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider compliance assessment via audiotapes and checklists
Number of subjects: 0
Study 8733032 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (habitual +50/100 mmol/day)
Number of subjects: 14
Study 8733032 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual salt intake
Number of subjects: 14
Study 8733032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (habitual -50/100 mmol/day)
Number of subjects: 14
Study 8733032 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 14
Study 8733032 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in salt intake (100 mmol/day)
Number of subjects: 14
Study 1613273 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 137
Study 1613273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 137
Study 6381101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotubation with lactated Ringer's solution
Number of subjects: 206
Study 6381101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotubation with hydrocortisone
Number of subjects: 206
Study 6381101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrotubation)
Number of subjects: 206
Study 6381101 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe disease
Number of subjects: 206
Study 6381101 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous pregnancies
Number of subjects: 206
Study 31845901 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice messages (n=43)
Number of subjects: 54
Study 31845901 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages (n=40)
Number of subjects: 54
Study 29916859 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 352
Study 29916859 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 352
Study 29916859 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 352
Study 26673352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus Gemcitabine (VG)
Number of subjects: 69
Study 26673352 — intervention group
Group type: COMPARATOR
Intervention: Vinflunine plus Carboplatin (VC)
Number of subjects: 69
Study 25037139 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 60 mg once a day 21/7
Number of subjects: 129
Study 25037139 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 80 mg once a day 14/14
Number of subjects: 129
Study 25037139 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg twice a day and cobimetinib 60 mg 28/0
Number of subjects: 129
Study 25037139 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib and cobimetinib (various dosing regimens)
Number of subjects: 129
Study 21985892 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Web-based module on injury prevention
Number of subjects: 57
Study 21985892 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive Web-based module on injury prevention (Control)
Number of subjects: 57
Study 21985892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modules (Interactive and Noninteractive)
Number of subjects: 57
Study 20139340 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-phosphate cement (Ca-P) used for indirect pulp-capping
Number of subjects: 0
Study 20139340 — intervention group
Group type: COMPARATOR
Intervention: Control (without Ca-P base)
Number of subjects: 0
Study 17392043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (reduction of body temperature by about 3 degrees C)
Number of subjects: 0
Study 17392043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia
Number of subjects: 0
Study 17012883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix (TIV)
Number of subjects: 956
Study 17012883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 956
Study 12150241 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated correction explanation
Number of subjects: 0
Study 12150241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive strategies and motivational priorities
Number of subjects: 0
Study 10214832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (2.5 mg, 5 mg, 10 mg, 15 mg) combined with 2 mg of micronized 17beta-estradiol
Number of subjects: 194
Study 7605019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at concentrations of 1, 3, 10, 30, and 100 ppm
Number of subjects: 6
Study 7605019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 6
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus ADR (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, and Adriamycin)
Number of subjects: 342
Study 2213103 — intervention group
Group type: COMPARATOR
Intervention: VAC alone (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin)
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus BPR (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, plus bilateral pulmonary radiotherapy)
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus ADR
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus BPR
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 342
Study 2213103 — intervention group
Group type: COMPARATOR
Intervention: Pelvic disease
Number of subjects: 342
Study 2213103 — intervention group
Group type: COMPARATOR
Intervention: Nonpelvic disease
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of metastatic disease
Number of subjects: 342
Study 2213103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of local recurrence
Number of subjects: 342
Study 87965 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 20 micrograms four times daily from surgery through the twelfth postoperative month
Number of subjects: 36
Study 87965 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study 87965 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 20 micrograms four times daily
Number of subjects: 36
Study 30939507 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (15 mg/kg IV before incision and a second identical dose 3 hours after the initial dose)
Number of subjects: 93
Study 30939507 — intervention group
Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 93
Study 30939507 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 93
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under normobaric conditions (101.3 kPa)
Number of subjects: 0
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 203 kPa hyperbaric condition
Number of subjects: 0
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 243 kPa hyperbaric condition
Number of subjects: 0
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump under 284 kPa hyperbaric condition
Number of subjects: 0
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump using ceftazidime 6 g under 203 kPa
Number of subjects: 0
Study 28357822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter elastomeric LV10 InfusorTM pump using ucloxacillin 8 g
Number of subjects: 0
Study 26194874 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Shoulder Arthroplasty (TSA)
Number of subjects: 24
Study 26194874 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty (RSA)
Number of subjects: 24
Study 26194874 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 24
Study 23401198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency supraorbital stimulation (400 Hz, 28 trains of nine stimuli)
Number of subjects: 14
Study 23401198 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 21480103 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d., Bismuth subcitrate 240 mg b.i.d. for two weeks
Number of subjects: 70
Study 21480103 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d. (without Bismuth)
Number of subjects: 70
Study 19806293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 72
Study 19806293 — intervention group
Group type: COMPARATOR
Intervention: No regular exercise (Control)
Number of subjects: 72
Study 19806293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Exercise and Control)
Number of subjects: 72
Study 17146320 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (18 mug)
Number of subjects: 20
Study 17146320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12663590 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid A1c availability
Number of subjects: 597
Study 12663590 — intervention group
Group type: COMPARATOR
Intervention: Routine A1c availability
Number of subjects: 597
Study 11001106 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector (Injex)
Number of subjects: 40
Study 11001106 — intervention group
Group type: COMPARATOR
Intervention: Needle syringe
Number of subjects: 40
Study 11001106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Jet injector and Needle syringe)
Number of subjects: 40
Study 9167112 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release glipizide
Number of subjects: 25
Study 9167112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9167112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (glipizide and placebo)
Number of subjects: 25
Study 8467322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion (5 mU/m2/min) during clamp A
Number of subjects: 6
Study 8467322 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin infusion (60 mU/m2/min) during clamp B
Number of subjects: 6
Study 8467322 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy (50 mg atenolol + 30 mg furosemide per day) prior to each clamp
Number of subjects: 6
Study 2431015 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% dermal cream
Number of subjects: 46
Study 2431015 — intervention group
Group type: COMPARATOR
Intervention: Lindane 1% lotion
Number of subjects: 46
Study 31219270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 6 weeks
Number of subjects: 267
Study 31219270 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study 30344655 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐time lavage group
Number of subjects: 120
Study 27120478 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA:IR measurement in women who developed puerperal infection
Number of subjects: 1180
Study 27120478 — intervention group
Group type: COMPARATOR
Intervention: HOMA:IR measurement in women who did not develop puerperal infection
Number of subjects: 1180
Study 27120478 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression controlling for confounders
Number of subjects: 1180
Study 27120478 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of elevated HOMA:IR
Number of subjects: 1180
Study 25550062 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly self-care and nutrition-education program delivered by case managers (intervention group, n=789)
Number of subjects: 1060
Study 25550062 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, n=271)
Number of subjects: 1060
Study 22844053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion group (23 patients)
Number of subjects: 50
Study 22844053 — intervention group
Group type: COMPARATOR
Intervention: Non-fusion group (24 patients)
Number of subjects: 50
Study 20420270 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased progesterone dosage
Number of subjects: 0
Study 20420270 — intervention group
Group type: COMPARATOR
Intervention: Standard progesterone dosage (Control)
Number of subjects: 0
Study 18488134 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based administration of PFDI-20
Number of subjects: 52
Study 18488134 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based administration of PFIQ-7
Number of subjects: 52
Study 18488134 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for web-based format
Number of subjects: 52
Study 15596631 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey administered to participants regarding attitudes, beliefs, and practices about ACP
Number of subjects: 700
Study 11703888 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 120
Study 11703888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific data analysis
Number of subjects: 120
Study 11703888 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Revitalization Act
Number of subjects: 120
Study 9164506 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication (360 degrees fundoplication)
Number of subjects: 72
Study 9164506 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hill operation
Number of subjects: 72
Study 9164506 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hill operation with intraoperative manometry (IOM)
Number of subjects: 72
Study 9164506 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hill operation without intraoperative manometry (IOM)
Number of subjects: 72
Study 7970589 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole lacquer
Number of subjects: 36
Study 7970589 — intervention group
Group type: COMPARATOR
Intervention: Placebo lacquer
Number of subjects: 36
Study 3300171 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30-60 mg daily for at least 3 weeks)
Number of subjects: 43
Study 3300171 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75-225 mg daily for at least 3 weeks)
Number of subjects: 43
Study 31081342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 6629
Study 30166290 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month self-rehabilitation programme in addition to botulinum toxin injections (BTIs) and conventional physiotherapy
Number of subjects: 220
Study 30166290 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injections (BTIs) alone and conventional physiotherapy
Number of subjects: 220
Study 27050709 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-suggested rest interval (RI)
Number of subjects: 27
Study 27050709 — intervention group
Group type: COMPARATOR
Intervention: Fixed 2 min rest interval (RI)
Number of subjects: 27
Study 26600066 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread with EOC (two bottles)
Number of subjects: 10
Study 26600066 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 10
Study 26600066 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread with EOC
Number of subjects: 10
Study 23089076 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label glycine at doses titrated to 0.8 g/kg/d for 8 weeks
Number of subjects: 18
Study 23089076 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind glycine
Number of subjects: 18
Study 23089076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23089076 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label glycine for another 12 weeks after the double-blind phase
Number of subjects: 18
Study 20434046 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 0
Study 20434046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0